Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q1367466> ?p ?o }
Showing triples 1 to 78 of
78
with 100 triples per page.
- Q1367466 subject Q22695562.
- Q1367466 subject Q7300121.
- Q1367466 subject Q7487449.
- Q1367466 subject Q8507014.
- Q1367466 subject Q8760205.
- Q1367466 subject Q9052781.
- Q1367466 abstract "An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication "The Economic Power of Orphan Drugs", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act of 1983 (ODA) and similar Acts in other regions of the world and also driven by "high-profile philanthropic funding." The period between 2001 to 2011 was the "most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals." For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an "impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs." By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs.By 2012,"the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success."".
- Q1367466 wikiPageExternalLink orphreg.htm.
- Q1367466 wikiPageExternalLink rare_6_en.htm.
- Q1367466 wikiPageExternalLink www.diahome.org.
- Q1367466 wikiPageExternalLink FindEducationalOffering.aspx?productID=23774&eventType=Meeting.
- Q1367466 wikiPageExternalLink default.htm.
- Q1367466 wikiPageExternalLink ucm119477.htm.
- Q1367466 wikiPageWikiLink Q1141267.
- Q1367466 wikiPageWikiLink Q12140.
- Q1367466 wikiPageWikiLink Q130146.
- Q1367466 wikiPageWikiLink Q1365309.
- Q1367466 wikiPageWikiLink Q1414593.
- Q1367466 wikiPageWikiLink Q1422850.
- Q1367466 wikiPageWikiLink Q1502740.
- Q1367466 wikiPageWikiLink Q16243283.
- Q1367466 wikiPageWikiLink Q16930739.
- Q1367466 wikiPageWikiLink Q17005864.
- Q1367466 wikiPageWikiLink Q170990.
- Q1367466 wikiPageWikiLink Q1758380.
- Q1367466 wikiPageWikiLink Q178194.
- Q1367466 wikiPageWikiLink Q194041.
- Q1367466 wikiPageWikiLink Q19882011.
- Q1367466 wikiPageWikiLink Q204727.
- Q1367466 wikiPageWikiLink Q2067922.
- Q1367466 wikiPageWikiLink Q206921.
- Q1367466 wikiPageWikiLink Q212322.
- Q1367466 wikiPageWikiLink Q2198549.
- Q1367466 wikiPageWikiLink Q22695562.
- Q1367466 wikiPageWikiLink Q238101.
- Q1367466 wikiPageWikiLink Q253623.
- Q1367466 wikiPageWikiLink Q270791.
- Q1367466 wikiPageWikiLink Q2752427.
- Q1367466 wikiPageWikiLink Q2912966.
- Q1367466 wikiPageWikiLink Q30.
- Q1367466 wikiPageWikiLink Q30612.
- Q1367466 wikiPageWikiLink Q323936.
- Q1367466 wikiPageWikiLink Q3265969.
- Q1367466 wikiPageWikiLink Q329987.
- Q1367466 wikiPageWikiLink Q358564.
- Q1367466 wikiPageWikiLink Q4164182.
- Q1367466 wikiPageWikiLink Q421239.
- Q1367466 wikiPageWikiLink Q424200.
- Q1367466 wikiPageWikiLink Q456854.
- Q1367466 wikiPageWikiLink Q458.
- Q1367466 wikiPageWikiLink Q467635.
- Q1367466 wikiPageWikiLink Q4914632.
- Q1367466 wikiPageWikiLink Q507154.
- Q1367466 wikiPageWikiLink Q507443.
- Q1367466 wikiPageWikiLink Q5412882.
- Q1367466 wikiPageWikiLink Q5570339.
- Q1367466 wikiPageWikiLink Q614165.
- Q1367466 wikiPageWikiLink Q6382470.
- Q1367466 wikiPageWikiLink Q638729.
- Q1367466 wikiPageWikiLink Q6583504.
- Q1367466 wikiPageWikiLink Q7103921.
- Q1367466 wikiPageWikiLink Q7250583.
- Q1367466 wikiPageWikiLink Q725307.
- Q1367466 wikiPageWikiLink Q7257410.
- Q1367466 wikiPageWikiLink Q7300121.
- Q1367466 wikiPageWikiLink Q7487449.
- Q1367466 wikiPageWikiLink Q7654795.
- Q1367466 wikiPageWikiLink Q8161.
- Q1367466 wikiPageWikiLink Q8507014.
- Q1367466 wikiPageWikiLink Q8760205.
- Q1367466 wikiPageWikiLink Q8880.
- Q1367466 wikiPageWikiLink Q902171.
- Q1367466 wikiPageWikiLink Q905049.
- Q1367466 wikiPageWikiLink Q9052781.
- Q1367466 wikiPageWikiLink Q929833.
- Q1367466 wikiPageWikiLink Q954845.
- Q1367466 comment "An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive.".
- Q1367466 label "Orphan drug".